Preclinical antibacterial products worldwide targeting priority pathogens 2023

Published by
Matej Mikulic,
Jul 22, 2024

In 2023, there were 43 antibacterial products in preclinical pipeline worldwide targeting mycobacterium tuberculosis. This statistic illustrates the number of preclinical antibacterial products worldwide targeting WHO priority single pathogens.

Number of preclinical antibacterial products worldwide targeting WHO priority single pathogens in 2023, by pathogen

PathogenNumber of products
Pseudomonas aeruginosa 94
Staphylococcus aureus 94
Klebsiella pneumoniae* 85
Escherichia coli* 84
Acinetobacter baumanii 65
Enterobacter spp.* 65
Enterococcus faecium 53
Streptococcus pneumoniae 52
Mycobacterium tuberculosis 43
Salmonella spp. 29
Clostridioides diffcile 24
Shigella spp. 22
Haemophilus influenzae 17
Showing entries 1 to 13 (17 entries in total)
Created with Highcharts 7.2.2PathogenNumber of products949494948585848465656565535352524343292924242222171766224444Pseudomonas aeruginosaStaphylococcus aureusKlebsiella pneumoniae*Escherichia coli*Acinetobacter baumaniiEnterobacter spp.*Enterococcus faeciumStreptococcus pneumoniaeMycobacterium tuberculosisSalmonella spp.Clostridioides diffcileShigella spp.Haemophilus influenzaeBroad G+/G-**Gram-negative**Not disclosedOther medically important pathogens
0102030405060708090100110

© Statista 2025
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

June 2024

Region

Worldwide

Survey time period

2023

Supplementary notes

Note: products with activity against multiple species are counted against each species.

*  Activity against CR and 3GC isolates is not always disclosed, and so species activity is represented.
** Activity against individual bacterial species was not provided.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Coronavirus: the pharma and medtech response "

Other statistics that may interest you Coronavirus: the pharma and medtech response

Pharma - before the pandemic

6

Treatments and vaccines

8

Focus: BioNTech and Moderna

7

Opinions on COVID-19 vaccines

6

Business impact

4

Medtech - before the pandemic

5

Ventilators and testing

7

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Antibiotic use in the UKPharmaceutical industry in the UKRespiratory disease in the UKDrug use in the United Kingdom (UK)State of health in the UK
All features, all contents, at all times: Learn more about our professional solutions.

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.